Vaccine News and Research

Latest Vaccine News and Research

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

Immune proteins called HLA molecules help to activate killer T cell responses against pathogens. But according to a study that will be published online on December 14th in the Journal of Experimental Medicine (www.jem.org), one particular group of HLA molecules cripples this activation, perhaps explaining why HIV-infected individuals who express these HLAs progress to AIDS more rapidly than others.

15 Dec 2009

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Dyadic International, Inc. ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").

15 Dec 2009

IOM issues review of national vaccine strategy

Reuters: To strengthen U.S. national vaccine strategy, the country "needs to establish a permanent group that advises the government on vaccine safety and spend more money to address safety concerns about vaccines," according to a report released Friday by the Institute of Medicine.

15 Dec 2009

NBC News examines 'fastest growing' vector-borne disease: Dengue

Dengue is the "fastest growing" vector-borne disease worldwide, NBC News' "World Blog" writes in a story examining the disease. "It used to be contained largely to south-east Asia, but has been spreading, and is now found in South America, Africa, south Asia and parts of Australia.

15 Dec 2009

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

The Microbicides Development Programme announced earlier today that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.

14 Dec 2009

National Vaccine Plan aims to protect Americans from vaccine-preventable illnesses

While vaccines help prevent many diseases in the United States, we lack immunization protection against several serious illnesses, says a new report from the Institute of Medicine that identifies priority areas for updating the National Vaccine Plan.

14 Dec 2009

Clinical trial of 2009 H1N1 influenza vaccine

HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.

13 Dec 2009

About 47M infected, 10,000 dead from H1N1 in U.S., CDC says

U.S. health officials on Thursday announced nearly 10,000 people in the U.S. had died from H1N1 (swine flu) since the virus was first reported in April, the New York Times reports.

11 Dec 2009

HTDS comments on its recent stock price activity

Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.

11 Dec 2009

HHS: Current research efforts and developments in influenza vaccine technologies

The U.S. Department of Health and Human Services (HHS) will host a three-hour educational program for the media to learn more about ongoing government research efforts to develop and apply new technologies in the making of seasonal and pandemic influenza vaccines.

11 Dec 2009

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

African-American women in South Carolina more likely to have cervical cancer than white women

African-American women in South Carolina are 37 percent more likely to have cervical cancer than white women and have a death rate that is about 61 percent higher, according to a study by researchers at the University of South Carolina's Arnold School of Public Health.

11 Dec 2009

Pertinent questions about H1N1 Influenza answered by NERAC

Municipalities in Massachusetts should assume that the H1N1 Influenza is now present in their communities, schools, and work places, and should take appropriate precautions to prevent the spread of this virus as well as the seasonal flu.

11 Dec 2009

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Researchers from the University of Pennsylvania and the University of Georgia have been awarded a five-year, $14.6 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health, to expand and extend work on the Eukaryotic Pathogen Genome Database Resource, http://EuPathDB.org.

11 Dec 2009

Pharmacies to provide H1N1, seasonal flu and pneumonia vaccinations under TRICARE program

The Department of Defense today issued an interim final rule designating pharmacies as providers for H1N1, seasonal flu and pneumonia vaccinations under its TRICARE program.

11 Dec 2009

Four new H1N1 influenza vaccination clinics scheduled by Macomb County Health Department

Four new H1N1 influenza vaccination clinics have been scheduled by the Macomb County Health Department. Everyone over 6 months of age can receive the vaccine at these clinics. They are free of charge and will take place Dec. 14, 17, 19 and 21 at Bethesda Christian Church in Sterling Heights.

11 Dec 2009

Researchers identify new biological pathway of H1N1 transmission to human population

A new biological pathway by which the H1N1 flu virus can make the jump from swine to humans has been discovered by researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley. Early test results indicate that a heretofore unknown mutation in one of the H1N1 genes may have played an important role in transmitting the virus into humans.

11 Dec 2009

Researchers find weakness in H1N1's method for evading detection by immune system

Researchers at Rice University and Baylor College of Medicine (BCM) have found what they believe is a weakness in H1N1's method for evading detection by the immune system.

11 Dec 2009

Initiation of multi-national Phase III study of Stimuvax announced

Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).

11 Dec 2009

Vaccine News and Research

Latest Vaccine News and Research

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

Dyadic International enters into collaboration agreement with The Scripps Research Institute

IOM issues review of national vaccine strategy

NBC News examines 'fastest growing' vector-borne disease: Dengue

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

National Vaccine Plan aims to protect Americans from vaccine-preventable illnesses

Clinical trial of 2009 H1N1 influenza vaccine

About 47M infected, 10,000 dead from H1N1 in U.S., CDC says

HTDS comments on its recent stock price activity

HHS: Current research efforts and developments in influenza vaccine technologies

Pfizer's Prevenar 13 granted European marketing authorization

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

African-American women in South Carolina more likely to have cervical cancer than white women

Pertinent questions about H1N1 Influenza answered by NERAC

NIH awards $14.6M for Eukaryotic Pathogen Genome Database Resource expansion

Pharmacies to provide H1N1, seasonal flu and pneumonia vaccinations under TRICARE program

Four new H1N1 influenza vaccination clinics scheduled by Macomb County Health Department

Researchers identify new biological pathway of H1N1 transmission to human population

Researchers find weakness in H1N1's method for evading detection by immune system

Initiation of multi-national Phase III study of Stimuvax announced

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in